THERAPEUTIC EFFECTS OF GENETICALLY ENGINEERED TOXIN (DAB486IL-2) IN PATIENT WITH CHRONIC LYMPHOCYTIC-LEUKEMIA

被引：33

作者：

LEMAISTRE, CF

ROSENBLUM, MG

REUBEN, JM

PARKINSON, DR

MENEGHETTI, CM

PARKER, K

SHAW, JP

DEISSEROTH, AB

WOODWORTH, T

机构：

[1] UNIV TEXAS,MD ANDERSON CANC CTR,DEPT HEMATOL,HOUSTON,TX 77025

[2] UNIV TEXAS,MD ANDERSON CANC CTR,DEPT CLIN IMMUNOL & BIOL THERAPY,HOUSTON,TX 77025

[3] UNIV TEXAS,MD ANDERSON CANC CTR,DEPT LAB MED,HOUSTON,TX 77025

[4] NCI,BETHESDA,MD 20892

[5] SERAGEN INC,HOPKINTON,MA

来源：

LANCET | 1991年 / 337卷 / 8750期

关键词：

D O I：

10.1016/0140-6736(91)92788-4

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In DAB486IL-2 the receptor-binding domain of native diphtheria toxin is replaced by human IL-2 sequences. This recombinant fusion protein is selectively cytotoxic for cells bearing high-affinity IL-2 receptors-eg, leukaemic cells. A patient with chronic lymphocytic leukaemia who did not respond to gamma interferon and conventional antileukaemic drugs has responded to DAB486IL-2.

引用

页码：1124 / 1125

页数：2

共 9 条

[1]

HOLTER W, 1987, J IMMUNOL, V138, P2917

[2]

KIYOKAWA T, 1989, CANCER RES, V49, P4042

[3]

LEMAISTRE CF, 1990, P AM ASSOC CANC RES, V31, pA1145

[4]

ROSOLEN A, 1989, BLOOD, V73, P1968